Exploring personalized treatment for recurrent gynecological cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the effectiveness of genomic sequencing and molecular tumor boards in guiding personalized treatment for patients with recurrent ovarian, cervical, or endometrial cancer. It consists of two parts: a retrospective analysis of past patient data and a prospective enrollment of 200 patients. The study aims to assess whether targeted therapies based on molecular profiling can lead to improved clinical outcomes. Data will be collected from multidisciplinary consultations and treatment responses following genomic sequencing.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with recurrent ovarian, cervical, or endometrial cancer referred for multidisciplinary consultation by a gynecological oncologist;
* Presence of at least one evaluable lesion;
* Willingness to participate in multidisciplinary consultation;
* Age 18 years or older;
* Sufficient tumor tissue for next-generation sequencing (NGS) with a tumor content greater than 32%;
* Informed consent provided by the participant, indicating understanding of the study procedures and willingness to participate.

Exclusion Criteria:

* Patients with concurrent malignancies;
* Pregnant patients.

Where it's running

• Sun Yat'sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting
• Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center
  Shenzhen, Guangdong, China Recruiting

Study contacts

• Principal investigator: Jihong Liu, PhD — Sun Yat'sen University Cancer Center
• Study coordinator: Xiaolin Luo, PhD
• Email: luoxl@sysucc.org.cn
• Phone: 15017599965

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• OPB-201 therapy for recurrent endometrial and platinum-resistant ovarian cancer

  A one-time treatment with a patient’s own T cells engineered to target PRAME is being tested to see if it is safe and what dose works best for adults with recurrent endometrial cancer or platinum-resistant ovarian cancer.

  Recruiting at 5 sites Phase 1 Outpace Bio, Inc. · San Francisco, California and 4 other locations · NCT07664735

• HPV monitoring after chemoradiotherapy for cervical cancer

  This project will test whether HPV detected on cervical swabs and in blood can find cancer recurrence in people with stage IB–IVA cervical cancer after curative chemoradiotherapy.

  Recruiting General University Hospital, Prague · Prague · NCT07493928

• New treatment for relapsed high-grade serous ovarian cancer

  This study is testing a new drug combined with standard treatments to see if it can help people with relapsed high-grade serous ovarian cancer feel better and manage their disease.

  Recruiting at 40 sites Phase 1/2 Merck Sharp & Dohme LLC · New Haven, Connecticut and 40 other locations · NCT06843447

• Combining pegylated liposomal doxorubicin and adebrelimab with or without mirabegron for relapsed ovarian cancer

  This study is testing a new treatment combination for adults with relapsed ovarian cancer to see if adding mirabegron to pegylated liposomal doxorubicin and adebrelimab makes it work better.

  Recruiting Phase 2/3 Obstetrics & Gynecology Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT06791460

• Treatment for platinum-resistant recurrent ovarian cancer using IN10018 and PLD

  This study is testing whether a new treatment combining IN10018 with a standard cancer drug can help people with platinum-resistant recurrent ovarian cancer feel better compared to a placebo.

  Recruiting Phase 2 InxMed (Shanghai) Co., Ltd. · Beijing · NCT06014528

• Using SBRT and Niraparib for Ovarian Cancer with Limited Progression

  This study is testing if combining a type of targeted radiation therapy with a cancer medication can help women with advanced ovarian cancer that has only spread a little bit feel better and live longer.

  Recruiting at 7 sites Phase 2 Institute of Cancer Research, United Kingdom · Leeds, Leeds and 6 other locations · NCT05990192

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.